Need help? Our team of experienced experts is here for you with full support.
AKA-407
AktiAmino™ Fmoc-trans-4-Hyp-OH
Cat. No.
AKA-407
CAS No.
88050-17-3
MF
C20H19NO5
MW
353.37
AktiAmino™ Fmoc-trans-4-Hyp-OH is an L-hydroxyproline derivative with an Fmoc-protected α-amino group, a free 4-hydroxyl group, and a free carboxyl group. It is used to incorporate 4-hydroxy-L-proline residues during solid-phase peptide synthesis.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Data
Description
Storage and Shipping
References
Product Name
AktiAmino™ Fmoc-trans-4-Hyp-OH
CAS No.
88050-17-3
MF
C20H19NO5
MW
353.37
Specification
99%
Documents
Certificate of Analysis (COA), Specification sheet, Safety Data Sheet (SDS/MSDS) etc.
Description
AktiAmino™ Fmoc-trans-4-Hyp-OH is an L-hydroxyproline derivative with an Fmoc-protected α-amino group, a free 4-hydroxyl group, and a free carboxyl group. It is used to incorporate 4-hydroxy-L-proline residues during solid-phase peptide synthesis. Packing: 1kg/bag,25kg/drum or as request Availability: In stock
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1].Kadam SM, Kansagra BP, Kale RV, Patil JP, Yemireddy VR, Bhadane SN, et al., inventors. Process for the preparation of teneligliptin. United States patent US9518048B2. 2016 Dec 13.
[2].Ravikumar V, Andrade M, Mulvey D, Cole DL, inventors. Carbocation scavenging during oligonucleotide synthesis. United States patent US5510476A. 1996 Apr 23.
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.